Gossamer Bio, Inc. (GOSS) Form 8-K — Jul 27, 2026
Gossamer Bio entered into a Rights Reacquisition Agreement with Chiesi to terminate their Collaboration and License Agreement, thereby regaining worldwide development and commercial rights to seralutinib. Under the terms, Chiesi will pay Gossamer $5 million to settle outstanding costs, while Gossamer assumes future milestone and royalty obligations to Chiesi upon commercialization, effectively securing the majority of the program's long-term economics. The company provided a regulatory update stating that following a Pre-NDA Type B meeting, the FDA characterized the statistical significance issues observed in the Phase 3 PROSERA study as review issues rather than filing issues.
Key figures
- Cash Position
- $57.0 million
- Chiesi Payment
- $5.0 million
- Debt Reduction
- $115.9 million
- Notes Exchanged
- $181.1 million
- Notes New Issued
- $65.2 million
- Notes Remaining
- $18.9 million
Price after filing
Close on the filing date to close N calendar days later (from $0.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.